Pharmafile Logo

News and Press Releases

Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate

Immune response successfully improved with second generation vaccine candidate4 November 2025 -- Saint-Herblain, France -- Valneva SE, a specialty vaccine company, today announced positive results of its Phase 1 clinical...

Category: BioManufacturing, Biotechnology, Clinical Trials, Drug Delivery, Other, Pharmaceutical
Posted: November 4, 2025

Valneva
communications@valneva.com
6 rue Alain Bombard, 44800 Saint-Herblain, France

Touchlight to Supply GMP dbDNA to Support University of Nottingham’s Clinical Study for a Next-Generation Vaccine for Zika Virus

21 August 2024 -- Hampton, UK -- Touchlight, an innovation-driven contract development and manufacturing organization (CDMO) specializing in enzymatic DNA production, is proud to announce the clinical supply of its proprietary...

Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: August 21, 2024

Touchlight
info@touchlight.com
Morelands & Riverdale Buildings Lower Sunbury Road Hampton TW12 2ER

Touchlight and GSK Sign License Agreement for Use of Enzymatic dbDNA Production Technology for mRNA Manufacturing

Agreement enables GSK access to enzymatic production technology for rapid GMP production of DNA template for mRNA vaccine manufacturing 23 July 2024 -- Hampton, UK -- Touchlight, an innovation-driven CDMO...

Category: BioManufacturing, Biotechnology, Other, Pharmaceutical
Posted: July 23, 2024

Touchlight
info@touchlight.com
Morelands & Riverdale Buildings Lower Sunbury Road Hampton TW12 2ER

Touchlight and LenioBio Collaborate to Accelerate Development of Protein Therapeutics for Pandemic Response

Touchlight to participate in LenioBio’s recently announced grant from CEPI 2 July 2024 -- Hampton, UK, and Düsseldorf, Germany -- LenioBio, a biotech company pioneering cell-free protein production, and Touchlight,...

Category: BioManufacturing, Biotechnology, Other, Pharmaceutical
Posted: July 2, 2024

Touchlight
info@touchlight.com
Morelands & Riverdale Buildings Lower Sunbury Road Hampton TW12 2ER

University of Liverpool to Use Touchlight’s Rapid Enzymatic dbDNA in Fully Personalised Neoantigen Cancer Vaccine Clinical Study

The UK’s Medical Research Council is funding a 10-patient phase 1 study to deliver rapid personalised treatment for lung cancer patients 3 April 2024 -- Hampton, UK -- Touchlight, a...

Category: Biotechnology, Clinical Trials
Posted: April 3, 2024

Touchlight
info@touchlight.com
Morelands & Riverdale Buildings Lower Sunbury Road Hampton TW12 2ER

Touchlight Awarded Tender to Supply Enzymatic dbDNA to CPI’s RNA Centre of Excellence

28 March 2024 -- Hampton, UK -- Touchlight, an innovation-driven CDMO enabling the development of genetic medicines with its doggybone DNA (dbDNA) technology and leaders in enzymatic DNA production, is...

Category: Biotechnology
Posted: March 28, 2024

Touchlight
info@touchlight.com
Morelands & Riverdale Buildings Lower Sunbury Road Hampton TW12 2ER